Vaccine has new developments to treat lung cancer

Vaccine has new developments to treat lung cancer
Vaccine has new developments to treat lung cancer
Reporter day easy reporter Li tumour hospital learn from Tianjin 24 November such as face such as moustache such as YunHong such as Li, academician of institute Chinese Academy of Engineering XiShan Hao this lead seminar in to make important progress at the lung cancer treatment of cellule. Researchers utilize trees to dash for ward form cells (DC) Killer cell (CIK) that vaccine and cell factor induce Treat lung cancer jointly, survival rate rise to 27% from 10.1% two year later period patient. Researchers find, DC vaccine playing a very important role in the human body resists malignant tumour and infective disease in recent years. Three clinical tests of DC vaccine that are launched recently reveal: The result is obvious in DC vaccine is in the malignant tumour treatment. CIK cell have resisting killing the tumour advantage of the tumour activity and wide table of natural killer cell's NK cells of T lymphocytes concurrently, the prospect that the co-operation of DC and CIK treats tumour is favoured by researchers. But DC unites the clinical treatment of CIK and is still at the starting stage, is used in treatment of systematic tumour of the blood more. Since 2004, Tianjin tumour hospital has launched DC and united the clinical research that CIK treatment is not cellule lung cancer. Researchers have chosen the person who didn't get cellule lung cancer and 70 persons who didn't get cellule lung cancer in later period after 50 operations, adopt DC to unite CIK and carry on the healing solution of regular chemotherapy at the same time. Found finally, the postoperative patient with later period employed DC, CIK to unite regular chemotherapy, the prominent extension of its life cycle. Compare simple the intersection of chemotherapy and group with, skill the intersection of future trouble person and two years total survival rate is improved from 78.8% to 94.7%, patient's survival rate of two years is improved from 10.1% to 27% in later period. Seminar members, Tianjin tumour hospital living beings treat head of the department Professor Ren XiuBao and claim, this research indicates vaccine has broad clinical application prospect in treating tumour.


|